Hepatitis-associated Aplastic Anemia.

Abstract

Hepatitis-associated aplastic anemia (HAAA) accounts for 4% of autoimmune hepatitis in children. An episode of seronegative autoimmune hepatitis is followed a few days or months later by aplastic anemia or full aplasia. This autoimmune disease could be due to a regulation defect in the immune response to a viral trigger, in a genetically predisposed individual. Other causes of hepatitis or aplastic anemia have to be ruled out. Steroids and azathioprine usually control the liver damage but do not prevent the development of aplastic anemia. Aplastic anemia is treated with either hematopoietic stem cell transplantation in patients with a sibling donor or anti-thymocyte globulins and cyclosporine. We propose guidelines to explore and treat this rare disease. We emphasize on the necessary close collaboration between hepatologists and hematologists.

• Authors: Maxime Gonnot, Florent Neumann, Frédéric Huet, Raphaëlle Maudinas, Thierry Leblanc, Florence Lacaille
• Journal: Journal of pediatric gastroenterology and nutrition (J Pediatr Gastroenterol Nutr) Vol. 75 Issue 5 Pg. 553-555 (11 01 2022) ISSN: 1536-4801 [Electronic] United States
• PMID: 36070526 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Chemical References

• Cyclosporine

Topics

• Child
• Humans
• Anemia, Aplastic (complications, therapy)
• Hepatitis, Autoimmune (complications, therapy)
• Cyclosporine (therapeutic use)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Siblings